The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shternis Y.V.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Mednova I.A.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Petkun D.A.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Kornetova E.G.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Ivanova S.A.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia;
Siberian State Medical University, Tomsk, Russia

Serum NOS1AP concentration: association with clinical schizophrenia polymorphism and metabolic syndrome

Authors:

Shternis Y.V., Mednova I.A., Petkun D.A., Kornetova E.G., Ivanova S.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(3): 167‑173

DOI: 10.17116/jnevro2026126031167

Read: 225 times

Buy for 300₽
Contact the author
Table of contents

SERUM NOS1AP CONCENTRATION: ASSOCIATION WITH CLINICAL SCHIZOPHRENIA POLYMORPHISM AND METABOLIC SYNDROME
SERUM NOS1AP CONCENTRATION: ASSOCIATION WITH CLINICAL SCHIZOPHRENIA POLYMORPHISM AND METABOLIC SYNDROME

To cite this article:

Shternis YV, Mednova IA, Petkun DA, Kornetova EG, Ivanova SA. Serum NOS1AP concentration: association with clinical schizophrenia polymorphism and metabolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(3):167‑173. (In Russ.)
https://doi.org/10.17116/jnevro2026126031167

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Asso­ciation of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15
Treatment and prevention of suture failure and bleeding after various bariatric inte­rventions. Piro­gov Russian Journal of Surgery. 2025;(5):79-85
Prevalence of meta­bolic syndrome among the indi­genous popu­lation in central Yaku­tia rural areas. Russian Journal of Preventive Medi­cine. 2025;(5):21-26
Effi­ciency of anthropometric surrogate indi­ces for the meta­bolic syndrome and its components diagnosing in middle-aged Moscow men. Russian Journal of Preventive Medi­cine. 2025;(5):41-48
Drinking mine­ral water for progressive resi­stance to insu­lin. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):24-30
Non-alcoholic fatty liver disease: a view formation on the problem and its significance for the clinical practice. Russian Journal of Preventive Medi­cine. 2025;(7):127-132
Priority areas for improving the regu­latory framework in the field of children and adolescents health protecting: the cardiometabolic diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(8):27-33
Abstract:

OBJECTIVE

To study the associations of the serum concentration of NOS1AP (Nitric Oxide Synthase 1 Adaptor Protein) with clinical polymorphism and components of metabolic syndrome (MS) in patients with schizophrenia.

MATERIAL AND METHODS

111 patients with schizophrenia (F20 according to ICD-10) and 22 healthy volunteers were included in the study. Patients underwent a comprehensive clinical, anthropometric, and laboratory examination. Serum NOS1AP was measured by enzyme-linked immunosorbent assay. Statistical data were processed using Statistica v.12.0 and GraphPad Prism v.8.0. Differences were considered statistically significant at p<0.05.

RESULTS

Serum NOS1AP levels in schizophrenia patients were significantly higher than in healthy subjects (p=0.0025). Also, NOS1AP was higher in patients with a predominance of negative symptoms (p=0.0377). In patients with a disease duration of 5 years or more, NOS1AP was significantly higher than in those with less than 5 years (p=0.0162) The type of schizophrenia had no significant effect on NOS1AP levels (p=0.4785). A statistically significant increase in serum NOS1AP levels was observed in patients with concomitant MS compared with those without MS (p=0.0081). In patients with abdominal obesity, serum NOS1AP levels were higher than in those with normal waist circumference (p=0.043). There were no statistically significant differences in NOS1AP levels depending on the presence of hypertension or dyslipidemia.

CONCLUSION

The found patterns suggest a common pathophysiological mechanism mediated by NOS1AP linking psychopathology to metabolic disorders.

Keywords:

schizophrenia
NOS1AP gene
metabolic syndrome

Authors:

Shternis Y.V.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Mednova I.A.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Petkun D.A.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Kornetova E.G.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Ivanova S.A.

Research Institute of Mental Health of the Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia;
Siberian State Medical University, Tomsk, Russia

Received:

21.11.2025

Accepted:

15.12.2025

Close metadata

References:

  1. Salari N, Maghami N, Ammari T, et al. Global prevalence of metabolic syndrome in schizophrenia patients: a systematic review and meta-analysis. Journal of Prevention. 2024;45(6):973-986.  https://doi.org/10.1007/s10935-024-00798-8
  2. Balashova AV, Machekhina LV, Mamleeva DV, et al. Metabolic adverse effects of antipsychotics: the state of the problem and management options. Ozhirenie i metabolizm. 2022;19(4):431-441. (In Russ.). https://doi.org/10.14341/omet12935
  3. Denysov EM. Prevalence of the metabolic syndrome in the patients with schizophrenia. Zhurnal psihiatrii i medicinskoj psihologii. 2012;1(28):100-108. (In Russ.). https://journal.dnmu.ru/index.php/Psychiatry/article/view/1405
  4. Matiiv AB, Moskalenko SE, Sergeeva OS, et al. NOS1AP interacts with α-synuclein and aggregates in yeast and mammalian cells. International Journal of Molecular Sciences. 2022;23(16):9102. https://doi.org/10.3390/ijms23169102
  5. Freudenberg F, Alttoa A, Reif A. Neuronal nitric oxide synthase (NOS1) and its adaptor, NOS1AP, as genetic risk factors for psychiatric disorders. Genes, Brain and Behavior. 2015;14(1):46-63.  https://doi.org/10.1111/gbb.12193
  6. Nasyrova RF, Moskaleva PV, Vaiman EE, et al. Genetic factors of nitric oxide’s system in psychoneurologic disorders. International Journal of Molecular Sciences. 2020;21(5):1604. https://doi.org/10.3390/ijms21051604
  7. Galkin SA, Kornetova EG, Mednova IA, et al. The Effect of Metabolic Syndrome and its Individual Components on the Duration of the QTc Interval in Different Gene Carriers of the Nitric Oxide Synthase-1 Adapter Protein Gene in Patients with Schizophrenia. Psihiatriya. 2025;23(2):48-56. (In Russ.). https://doi.org/10.30629/2618-6667-2025-23-2-48-56
  8. Orlov PS, Ivanoshchuk DE, Ivanova AA, et al. Association of polymorphisms KCNN2 and NOS1AP with sudden cardiac death. Rossijskij kardiologicheskij zhurnal. 2018;(10):59-63. (In Russ.). https://doi.org/10.15829/1560-4071-2018-10-59-63
  9. Kuznetsova LA, Basova NE. The role of the neural NO synthase adapter protein in the pathogenesis of metabolic syndrome and type 2 diabetes mellitus. Sibirskij nauchnyj medicinskij zhurnal. 2023;43(5):34-49. (In Russ.). https://doi.org/10.18699/SSMJ20230504
  10. Kurkin DV, Abrosimova EE, Bakulin DA, et al. Activity modulation of various nitric oxide syntases as an approach to endothelial dysfunction therapy. Pharmacy & Pharmacology. 2022;10(2):130-153. (In Russ.). https://doi.org/10.19163/2307-9266-2022-10-2-130-153
  11. Lourenço CF, Laranjinha J. Nitric oxide pathways in neurovascular coupling under normal and stress conditions in the brain: strategies to rescue aberrant coupling and improve cerebral blood flow. Frontiers in Physiology. 2021;12:729201. https://doi.org/10.3389/fphys.2021.729201
  12. Yazykova AB, Novoselova AE, Tsarkov IE, et al. Identification of biomarkers of schizophrenia using mass spectrometry methods (literature review). Sibirskij vestnik psihiatrii i narkologii. 2023;1(118):71-81. (In Russ.). https://doi.org/10.26617/1810-3111-2023-1(118)-71-81
  13. Hernandez K, Swiatkowski P, Patel MV, et al. Overexpression of isoforms of nitric oxide synthase 1 adaptor protein, encoded by a risk gene for schizophrenia, alters actin dynamics and synaptic function. Frontiers in Cellular Neuroscience. 2016;10:6.  https://doi.org/10.3389/fncel.2016.00006
  14. Li LL, Ginet V, Liu X, et al. The nNOS-p38MAPK pathway is mediated by NOS1AP during neuronal death. The Journal of Neuroscience. 2013;33(19):8185-8201. https://doi.org/10.1523/JNEUROSCI.4578-12.2013
  15. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. Journal of Internal Medicine. 2007;262(2):173-183.  https://doi.org/10.1111/j.1365-2796.2007.01830.x
  16. Nasykhova YA, Tonyan ZN, Mikhailova AA, et al. Pharmacogenetics of type 2 diabetes: progress and prospects. International Journal of Molecular Sciences. 2020;21(18):6842. https://doi.org/10.3390/ijms21186842
  17. Mu K, Sun Y, Zhao Y, et al. Hepatic nitric oxide synthase 1 adaptor protein regulates glucose homeostasis and hepatic insulin sensitivity in obese mice depending on its PDZ binding domain. EBioMedicine. 2019;47:352-364.  https://doi.org/10.1016/j.ebiom.2019.08.033
  18. Ronchi C, Bernardi J, Mura M, et al. NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis. Cardiovascular Research. 2021;117(2):472-483.  https://doi.org/10.1093/cvr/cvaa036
  19. Limankina IN. Long QT interval syndrome and problems of safety of psychopharmacotherapy. Vestnik aritmologii. 2008;52(52):66-71. (In Russ.). https://vestar.elpub.ru/jour/article/view/369
  20. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13(2):261-276.  https://doi.org/10.1093/schbul/13.2.261
  21. Mosolov SN. Scales of psychometric assessment of schizophrenia symptoms and the concept of positive and negative disorders. M. 2001. (In Russ.).
  22. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome — a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-480.  https://doi.org/10.1111/j.1464-5491.2006.01858.x
  23. Shmukler AB. Shizophrenia. M.: GEOTAR-Media. 2017. (In Russ.).
  24. Delorme R, Betancur C, Scheid I, et al. Mutation screening of NOS1AP gene in a large sample of psychiatric patients and controls. BMC Medical Genetics. 2010;11:108.  https://doi.org/10.1186/1471-2350-11-108
  25. Xu B, Wratten N, Charych EI, et al. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Medicine. 2005;2(10):e263. https://doi.org/10.1371/journal.pmed.0020263
  26. Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Frontiers in Cellular Neuroscience. 2013;7:31.  https://doi.org/10.3389/fncel.2013.00031
  27. Mednova IA, Pozhidaev IV, Tiguntsev VV, et al. NOS1AP gene variants and their role in metabolic syndrome: a study of patients with schizophrenia. Biomedicines. 2024;12(3):627.  https://doi.org/10.3390/biomedicines12030627
  28. Tiguntsev VV, Mednova IA, Petkun DA, et al. NOS1AP gene polymorphism and body fat in patients with schizophrenia: a search for associations. Molekulyarnaya biologiya. 2025;59:101-108. (In Russ.). https://doi.org/10.1134/S0026893324700730
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.